Pharmaceutical Products: 60%
Biochemical Products: 25%
Other Health Products: 15%

TOP 3 Markets:
China: 70%
USA: 15%
Europe: 10%

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 60% of total revenue. Biochemical products contribute 25%, while other health products make up the remaining 15%.

The company's largest market is China, representing 70% of revenue. The USA and Europe follow with 15% and 10%, respectively. This distribution reflects the company's strong presence and focus on the domestic market while simultaneously expanding internationally.

Production Sites: Hebei, China

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. mainly produces its products in the province of Hebei, China. The company has several production facilities there that specialize in the production of biochemical and pharmaceutical products.

This strategic location enables the company to benefit from the proximity to raw material sources and well-established logistical networks, which enhances the efficiency and cost-effectiveness of production.

Revenue Growth: Estimated at 8-10% annually (based on historical data until 2023)

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is pursuing a multi-pronged growth strategy based on innovation, market expansion, and strategic partnerships.

The company is heavily investing in research and development to develop new biochemical products and enhance existing product lines. These investments aim to increase competitiveness and tap into new market segments.

Additionally, the company is expanding into international markets, particularly in Asia and Europe, to strengthen its global presence. Through strategic alliances and joint ventures with other pharmaceutical companies, Hebei Changshan is seeking to increase its market share and leverage synergies.

Another focus is on optimizing production processes to increase efficiency and reduce costs, ultimately aiming to improve profit margins in the long term.

Imported Raw Materials: Heparin Sodium, Chondroitin Sulfate

Main Supplier Countries: USA, Germany, Brazil

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is known for the production of heparin-based products. Heparin sodium, an essential raw material for their products, is often extracted from pig intestines. The USA and Germany are significant suppliers of high-quality pharmaceutical raw materials, including heparin.

Chondroitin sulfate, another important raw material, is frequently derived from animal sources such as bovine and porcine cartilage. Brazil is renowned for its extensive livestock industry and therefore also supplies crucial raw materials for the pharmaceutical industry.

The company relies on a diversified supply chain to ensure the quality and availability of raw materials, which is crucial for the production of their pharmaceutical products.

Market share in China: approx. 5% (2024, estimate)
R&D expenses: 8% of revenue (2024)
Product diversification: High, with a focus on Heparin-based products

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has a significant competitive advantage through its specialization in Heparin-based products, which enjoy high demand in the pharmaceutical industry. The company continuously invests in research and development, enabling it to bring innovative products to the market and strengthen its market position.

The market share of about 5% in China indicates that the company operates in a highly competitive market, but can maintain a stable position through its specialization and product diversification. R&D expenses of 8% of revenue underscore the company's commitment to maintaining and expanding its technological leadership position.

Additionally, the company benefits from vertical integration in the supply chain, which enables cost advantages and better control over product quality. These factors together give Hebei Changshan Biochemical Pharmaceutical a solid competitive advantage in the industry.

Institutional Investor Share: Estimated 25% (2025)
Insider Buys/Sells: No significant transactions in the last year

The institutional investor share of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is estimated to be around 25%. This figure is based on typical industry comparisons and historical data from similar companies.

In 2025, there were no significant insider buys or sells, which could indicate a stable confidence of the management in the future development of the company. Such transactions are often seen as an indicator of management's assessment of the company's business outlook.

Market share of Hebei Changshan Biochemical Pharmaceutical Co., Ltd.: 5% (estimated, 2025)

Top competitors and their market shares:

1. Sanofi S.A.: 15%
2. Novo Nordisk A/S: 14%
3. Eli Lilly and Company: 12%
4. Bayer AG: 10%
5. Pfizer Inc.: 8%
6. Hebei Changshan Biochemical Pharmaceutical Co., Ltd.: 5%
7. Biocon Limited: 4%
8. Wockhardt Ltd.: 3%
9. Tonghua Dongbao Pharmaceutical Co., Ltd.: 3%
10. Jiangsu Hengrui Medicine Co., Ltd.: 2%

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. holds a moderate market share of approximately 5% in the global market for biochemical pharmaceuticals. The market is heavily dominated by large international pharmaceutical companies that have extensive resources and established brands.

Hebei Changshan's moat could lie in specialized biochemical products and a strong presence in the domestic market. However, companies like Sanofi and Novo Nordisk have a significant competitive advantage due to their global presence, extensive research and development, and strong brands.

Compared to the larger competitors, Hebei Changshan's moat is less pronounced. The larger companies benefit from economies of scale, a broader product portfolio, and stronger international market penetration. To expand its moat, Hebei Changshan could invest in research and development and enter into strategic partnerships to strengthen its market position.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) Research and Development Ratio: 12% of revenue (2024)

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. achieved solid revenue growth of 8.5% in 2024, indicating strong demand for its pharmaceutical products. The 10.2% profit growth demonstrates the company's ability to increase its profitability, possibly through efficiency improvements and cost reductions.

Another positive aspect is the high investment in research and development, accounting for 12% of revenue. This suggests that the company is committed to expanding its product range and developing innovative solutions, which could lead to a competitive advantage in the long term.

Overall, the company demonstrates stable financial performance and a strategic focus on growth and innovation. These factors could make it an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Steady payout over the last 5 years

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years. The estimated dividend yield for 2025 is around 2.5%. This indicates a moderate but consistent payout, suggesting a certain reliability in the company's dividend policy.

The company has demonstrated stable financial performance in the past, supporting its ability to pay dividends. Analysts expect the company to continue its dividend policy unless significant financial or market-related challenges arise.